Treg Cell Activation Without Feeder Cells Using Chimeric Polypeptides
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for culturing immune cells, such as Treg cells, are time-consuming and require feeder cells, leading to inefficiencies and the need for complex purification processes, while existing Treg cell therapies face challenges in enhancing proliferation and functionality, particularly in addressing inflammasome-related and senescent cell-related diseases.
Innovation Solution
A method involving the use of single-chain or multi-chain chimeric polypeptides with a soluble tissue factor domain, combined with CD3/CD28-binding agents or IL-2 receptor-activating agents, to stimulate Treg cell proliferation in a liquid culture medium, potentially enhanced by IgG1 antibody constructs, to improve Treg cell purity and functionality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If feeder cells are used in immune cell culture methods, then cell proliferation is supported, but device complexity and purification requirements increase
Solution Approach 1:
The patent extracts and eliminates the feeder cell component from the culture system, replacing it with defined cytokine compositions. This removes the complexity associated with feeder cell maintenance, purification, and contamination risks while preserving the essential function of supporting immune cell proliferation through alternative biochemical signals.
Solution Approach 2:
The patent introduces cytokines as intermediary substances that mediate the proliferative signal previously provided by feeder cells. These cytokines act as soluble mediators that can be precisely controlled in concentration and composition, replacing the complex cell-cell interactions with a more manageable biochemical system.
2Quantity of substance
If culture time is extended to achieve therapeutically effective cell numbers, then sufficient immune cells are obtained, but loss of time and resource efficiency increase
Solution Approach 1:
The patent optimizes multiple culture parameters simultaneously, including cytokine concentrations, ratios, and combinations, to accelerate proliferation kinetics. By carefully adjusting these parameters, the system achieves therapeutically effective cell numbers in shorter timeframes compared to conventional methods, reducing both time loss and resource consumption.
Solution Approach 2:
The patent establishes continuous proliferative signaling through optimized cytokine compositions that maintain sustained activation of proliferation pathways. This continuous useful action prevents culture plateaus and ensures steady expansion of immune cell populations throughout the culture period, maximizing output efficiency.
3Productivity
If conventional culture methods are used, then immune cells can be expanded, but Treg cell functionality and purity are compromised
Solution Approach 1:
The patent develops a universal cytokine composition platform that simultaneously achieves multiple objectives: supporting robust cell expansion while maintaining Treg cell purity and functionality. The cytokine mixture is designed to provide signals that are specific to Treg cell differentiation and maintenance, avoiding signals that would promote differentiation into other T cell lineages.
Solution Approach 2:
The patent tailors the cytokine composition specifically for Treg cell culture requirements, creating a localized optimal environment that differs from conventional universal immune cell culture conditions. This localized optimization ensures that the culture conditions specifically support Treg cell properties rather than generic immune cell expansion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances Treg cell proliferation and functionality, enabling more effective clearance of senescent cells and reducing inflammasome activation, thereby addressing chronic inflammation and associated diseases.
Implementation Method 1
single-chain chimeric polypeptides that include a soluble tissue factor domain or multi-chain chimeric polypeptides that include a soluble tissue factor domain, in combination with CD3/CD28-binding agents
Implementation Method 2
IL-2 receptor-activating agents, to stimulate Treg cell proliferation
Data Source
AI summary
Provided herein are methods of stimulating or increasing the proliferation of a Treg cell, compositions including a population of Treg cells generated by these methods, and methods of treating a subject using these compositions.